3 Sept 2026Open access
Melatonin seed priming reconfigures the metabolomic profile and functional attributes of brown mustard (Brassica juncea L.) sproutsPublisher siteScientific Reports, Circadian rhythm and melatonin
Active, last published 2026
In microrna in disease regulation
Tarek M.
Okda
Scholar“Research focused on MicroRNA in disease regulation and adjacent fields.”
Damanhour University
Egypt
Claim Your ProfileEgypt0
H-index
0
Citations
Tarek has not officially claimed their profile. If you are Tarek, claim it free.
Claim Your Profile
Pioneer
LOCKED
Pathfinder
LOCKED
Scholar
EARNED
Innovator
LOCKED
Inventor
LOCKED
Catalyst
LOCKED
Expert
UPGRADE
01 · About the work
What I study
arek M. Okda is a researcher working on MicroRNA in disease regulation. A fuller summary will appear once they update their profile.
02 · Reach
Publication output and reach
Tarek's work has been cited 0 times across 1 active year. Bars show publications per year; the line shows cumulative citation totals across publications first appearing in each year.
03 · Research focus
Topics
MicroRNA in disease regulation×1
04 · Where I am
Affiliations
Affiliation on published researchDamanhour University, EgyptDrawn from the institution listed on this researcher’s published work.
Research themes (UN SDGs)
05 · Selected work
Recent publications
2 works14 Aug 2026Open access
Circulating miRNA-122 and miRNA-223 expression signatures across TNM stages of hepatocellular carcinoma in Egyptian patients: association with angiogenesis, apoptosis, and autophagy-related biomarkersPublisher siteEgyptian Liver Journal, MicroRNA in disease regulation
Expert Academic Profiles go further
Citation trend analytics, exportable publication records, and direct enquiry routing from industry and funders.
Are you Tarek?
Claim it to verify your details, connect with industry partners, and explore Fractional Domain Expert opportunities through MARATTO™.
African researchers are full of potential that too often goes unrecognised. Your MARATTO™ profile gives your work the commercial pathway it deserves.
Claim Your Profile
Free to claim · takes a minute to verify it’s you